Data / Form D filings / Cellebration Life Sciences, Inc.
Cellebration Life Sciences, Inc.: Form D filings
Cellebration Life Sciences, Inc., a biotechnology company in Phoenix, AZ, filed 4 Form D notices with the SEC between 2021 and 2023. The latest, on August 21, 2023, reports $2.8 million sold of a $20 million offering to 63 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 12601 N. CAVE CREEK ROAD, SUITE 111, Phoenix, AZ, 85022
- Phone
- (602) 601-5293
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Wyoming
- Year incorporated
- 2020
- Revenue range
- $1,000,001 - $5,000,000
- Exemptions claimed
- Rule 506(c)
- SEC identifier (CIK)
- 1863013
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 21, 2023 | Amendment | $20,000,000 | $2,804,527 | $17,195,473 | 63 | Jan 18, 2021 | sec.gov |
| Jun 13, 2022 | Amendment | $20,000,000 | $1,290,000 | $18,710,000 | 14 | Jan 18, 2021 | sec.gov |
| May 31, 2022 | Amendment | $20,000,000 | $1,290,000 | $18,710,000 | 14 | May 17, 2021 | sec.gov |
| Jun 2, 2021 | New notice | $20,000,000 | $285,000 | $19,715,000 | 7 | May 17, 2021 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Anand Srivastava | Director | |
| Deven Patel | Director | |
| Bill Deegan | Director | |
| Tim Kopatich | Executive Officer |
Other biotechnology companies in Arizona that filed recently
- Gut-Brain-Axis Therapeutics Inc. $2 million · Oct 27, 2026
- Avery Therapeutics, Inc. $8.5 million · Sep 21, 2026
Every Form D from the week of Aug 21, 2023 · All recent filings in Arizona · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Cellebration Life Sciences, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.